We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Fintel reports that on October 23, 2024, CLSA initiated coverage of Charles River Laboratories International (NYSE:CRL) with a Underperform recommendation. As of October 22, 2024, the average one ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at a third-party manufacturer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback